Early Immune System Development and Ontogeny (R01 Clinical Trial Optional)
National Institutes of Health
Award ceiling
—Award floor
—Posted
Dec 30, 2024Closes
Nov 5, 2028Location eligibility
No specific state restriction found in this listing — check the full opportunity for details.Categories: Health, Income Security and Social Services
Eligible applicants: Independent school districts, Public and State controlled institutions of higher education, For profit organizations other than small businesses, City or township governments, Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Private institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, State governments, Small businesses, Others (see text field entitled "Additional Information on Eligibility" for clarification), County governments, Native American tribal organizations (other than Federally recognized tribal governments), Special district governments, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Description
The purpose of this Notice of Funding Opportunity (NOFO) is tofurther elucidate the mechanisms of early immune development in utero, during the early post-natal period and during early childhood in neonates, infants, and children and adolescents with or without in-utero exposure to HIV or Anti-Retroviral Therapeutics (ART).This initiative aims to understand intricate mechanisms of immune cells at the maternal-fetal interface, T and B cell development and maturation in offspring, and local immune responses and the role of systemic immunity.